Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO
Cardio Diagnostics — Investor Presentation (February 2025)
41 slides from Cardio Diagnostics's investor presentation, Feb 21, 2025
Slide 1: Leading the Next Frontier in Precision Cardiovascular Medicine
Leading the Next Frontier in Precision Cardiovascular Medicine 2025 Revolutionizing Cardiovascular Medicine With Epigenetics and AI
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements and information included in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this presentation, the words or phrases “will”, "will likely result," "expected to," "
Slide 3: Key Investment Highlights
Key Investment Highlights Cardio Diagnostics (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more accessible, personalized and precise Cardio Diagnostics is headquartered in Chicago, Illinois La
Slide 4: Key Investment Highlights
Key Investment Highlights Cardio Diagnostics' clinical tests are: More sensitive compared to current lipid-based clinical tests and stress ECG Non-invasive blood tests that can be administered remotely or in provider settings Cardio Diagnostics' clinical tests and platforms provide clear value propo
Slide 5: Mission to Revolutionize Cardiovascular Medicine with Epigenetics and AI
Cardio Diagnostics’ Mission is to Revolutionize Cardiovascular Medicine with Epigenetics and AI Our Vision: Precision Cardiovascular Medicine, driven by epigenetics and artificial intelligence, will transform the delivery of targeted interventions, enhance patient outcomes, and reduce costs, ultimat
Slide 6: Pioneering a New Era in Precision Cardiovascular Medicine
Cardio Diagnostics is Pioneering a New Era in Precision Cardiovascular Medicine Driven by Innovation, Diversification, Scale and Experience INNOVATION DIVERSIFICATION Only precision molecular diagnostics technology for Multiple launched and in development synergistic cardiovascular disease at the in
Slide 7: Pioneering a New Era: Scale and Experience
Cardio Diagnostics is Pioneering a New Era in Precision Cardiovascular Medicine Driven by Innovation, Diversification, Scale and Experience SCALE EXPERIENCE Highly scalable and efficient testing and reporting Has profound understanding of clinical needs, process. challenges and opportunities. Favora
Slide 8: Cardiovascular Disease is the Leading Cause of Death Globally
Cardiovascular Disease is the Leading Cause of Death Globally Despite Being Largely Preventable Cardiovascular disease (CVD) is the leading cause of death globally, accounting for nearly 19 million deaths per year, or about 32% of all global deaths ⁽¹⁾ Globally, cardiovascular disease is expected to
Slide 9: Cardiovascular Disease is a Burden for All Major Stakeholders
Cardiovascular Disease is a Burden for All Major Stakeholders Employers Providers and Provider Payers Organizations Employers may face increased Heart disease accounts for approximately Heart disease is responsible for a healthcare costs due to heart disease, as 25% of emergency room visits related
Slide 10: Four Strategic Priorities to Realize Our Vision
Four Strategic Priorities to Realize Our Vision Expand evidence portfolio that matters to key healthcare stakeholders Build upon current rigorous clinical validation and real world case studies Perform additional health economic studies to demonstrate substantial savings and ROI Establish a robust a
Slide 11: Clinicians' Current Approach to Assessing Risk and Detecting CVD
Clinicians’ Current Approach to Assessing Risk for and Detecting Cardiovascular Disease (CVD) Currently, risk for CVD is assessed using two Currently, CVD is detected using several tests: common lipid-based clinical tests: FRAMINGHAM RISK SCORE Exercise ECG Cardiac Catheterization (FRS) Measures the
Slide 12: Two Types of DNA Biomarkers Power Our Approach
Two Types of DNA Biomarkers Power Our Approach GENETICS (SINGLE NUCLEOTIDE POLYMORPHISMS) Inherited from parents <20% of risk for cardiovascular disease is driven by genetics⁽¹⁾ Does not change over time (i.e., not dynamic) EPIGENETICS (DNA METHYLATION) Influenced by lifestyle & environment Larger d
Slide 13: Our AI-Driven Integrated Epigenetic-Genetic Engine
Our AI-Driven Integrated Epigenetic-Genetic Engine™ Proprietary Engine designed and built over more than a decade BIG DATA HIGH-PERFORMANCE DOMAIN EXPERTISE PRODUCT COMPUTING, ML/AI AND DOMAIN EXPERTISE Billions of genetic, Non-linear data Lab translation of Lab profiling using epigenetic and mining
Slide 14: Cardio Diagnostics' Suite of Solutions
Cardio Diagnostics’ Suite of Solutions Clinical solutions: Non-clinical solutions: Epi+Gen CHD™ PrecisionCHD™ CardioInnovate360™ Only epigenetics-based clinical blood test in the world Only epigenetics-based clinical blood test in the world Research-use-only (RUO) solution to support the discovery,
Slide 15: Our Suite of Solutions Offer Unparalleled Innovation
Our Suite of Solutions Offer Unparalleled Innovation Current Clinical Solutions Evidence Utilize traditional, proxy biomarkers (e.g., lipid) that are Utilize biological blueprint biomarkers that go beyond 67% of patients who had a heart attack had normal total necessary but not sufficient traditiona
Slide 16: Differentiated Solutions Deliver Value to Key Healthcare Stakeholders
Our Differentiated Solutions Deliver Value to Key Healthcare Stakeholders Patients Employers Reduce absenteeism Improve well-being and improve and quality of life productivity among Receive timely and employees better care Reduce healthcare costs by avoiding costly disease management Providers Life
Slide 17: Clear, Key Differentiations for Coronary Heart Disease
Clear, Key Differentiations for Coronary Heart Disease Hospitals & GROWTH STRATEGIES Clinics SENSITIVE EPIGENETICS BASED TEST CORONARY HEART DISEASE SPECIFIC PHYSICIAN ORDERED AND/OR INTERPRETED AT-HOME TESTING AVAILABLE MULTIPLE DNA BIOMARKERS-BASED TEST MONITOR TREATMENT RESPONSE ⁽¹⁾ ⁽¹⁾ Compariso
Slide 18: A $185B US Total Addressable Market
Epi+Gen CHD™ and PrecisionCHD™: A $185B US Total Addressable Market⁽¹⁾ We expect to accelerate the Epi+Gen CHD™ is recommended We intend to accelerate the adoption of Epi+Gen CHD™ and for: adoption of both tests by: PrecisionCHD™ across several Adults ages 35-75 channels including: Have not been dia
Slide 19: The Integrated Genetic-Epigenetic Engine Can be Leveraged Repeatedly
The Integrated Genetic-Epigenetic Engine™ Can be Leveraged Repeatedly Assumes one patient could be tested with multiple tests⁽¹⁾ IN IN IN LAUNCHED LAUNCHED DEVELOPMENT DEVELOPMENT DEVELOPMENT TOTAL $340B Epi+Gen CHD PrecisionCHD CHF Risk Stroke Risk Diabetes Risk U.S. ADDRESSABLE MARKET 146M adults
Slide 20: A Scalable Testing & Reporting Process
A Scalable Testing & Reporting Process to Fulfill Increasing Demand REMOTE Telemedicine provider At-home lancet sample orders test for patient collection kit shipped to patient 1a 2a 3 4 5 6 7 Collect blood Ship blood Lab processing Process data Share patient 1b 2b sample sample overnight of blood a
Slide 21: Pursuing A New Standard of Care for Cardiovascular Medicine
Pursuing A New Standard of Care for Cardiovascular Medicine EVIDENCE ENGAGE FDA BUILDING PAYORS REIMBURSEMENT COVERAGE Continued expansion of analytical Completed first pre-submission Continued engagement of payors validity, clinical validity, clinical CODES with the FDA. Evaluating additional & PAY
Slide 22: Robust Short-Term & Long-Term Strategic Initiatives
Robust Short-Term & Long-Term Strategic Initiatives GROWTH STRATEGIES INCREASE REVENUE MANAGE RISKS REDUCE VARIABLE COSTS INTERNAL LAB PURSUE FDA PATHWAY PAYOR COVERAGE TARGET MULTIPLE REVENUE CHANNELS LAUNCH MULTIPLE SYNERGISTIC PRODUCTS © Cardio Diagnostics Holdings Inc., 2025. All rights reserved
Slide 23: Strong Leadership
Strong Leadership Experienced leadership, complementary backgrounds & vision to succeed Warren Hosseinion, MD Meesha Dogan, PhD Chairman CEO, Co-Founder, & Director President, Nutex Health, Inc. (NUTX) 15+ years bridging engineering, AI, and medicine Co-founder of Astrana Health (ASTH) Co-inventor o
Slide 24: Team Continued
Team Continued Robert Philibert, MD PhD Tim Dogan, PhD Elisa Luqman, JD MBA CTO CFO CMO, Co-Founder & Director Chief Legal Officer (SEC), Nutex Health, Inc. (NUTX) 17+ years in epigenetics and clinical translation 15+ years in AI and high performance computing systems Co-founder of bigVault Storage
Slide 25: Key Milestones Achieved
Key Milestones Achieved Revenue and Partnerships Secured the Innovative Technology contract with Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. Vizient's customer base encompasses over 60% of hospitals and 97% of academic medical centers in the US. Ex
Slide 26: Risk Factors
Risk Factors Our business is subject to numerous risks and uncertainties, including those highlighted in the section titled “Risk Factors,” which represent challenges that we face in connection with the successful implementation of our strategy and growth of our business. The occurrence of one or mo
Slide 27: Risk Factors
Risk Factors Risks Related to Government Regulation We conduct business in a heavily regulated industry, and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which c
Slide 28: For more information, please email
For more information, Revolutionizing Cardiovascular please email: Medicine With Epigenetics & AI investors@cdio.ai © Cardio Diagnostics Holdings Inc., 2025. All rights reserved.
Slide 29: Appendix
APPENDIX Revolutionizing Cardiovascular Medicine With Epigenetics and AI
Slide 30: Cardiovascular Disease and Associated Co-Morbidities
Cardiovascular Disease and Associated Co-Morbidities In the US, nearly 18 million Americans have some type of cardiovascular disease (CVD), and CVD is responsible for both 1 in every 4 deaths and nearly $1 billion/day in medical costs + lost productivity.⁽¹⁾⁽²⁾ CORONARY HEART CONGESTIVE HEART STROKE
Slide 31: Epi+Gen CHD: The Only Epigenetics-Based Test For CHD Event Risk Assessment
Epi+Gen CHD™: The Only Epigenetics-Based Test For Coronary Heart Disease Event Risk Assessment Epi+Gen CHD™ is Cardio Diagnostics’ first product that was developed using our AI-driven Integrated Genetic-Epigenetic Engine™ and was validated in collaboration with Intermountain Healthcare. Epi+Gen CHD™
Slide 32: PrecisionCHD: The Only Epigenetics-Based Test For CHD Detection
PrecisionCHD™: The Only Epigenetics-Based Test For Coronary Heart Disease Detection PrecisionCHD™ is Cardio Diagnostics’ second product that was developed using our AI-driven Integrated Genetic-Epigenetic Engine™ and was validated in collaboration with Intermountain Healthcare and University of Iowa
Slide 33: Actionable Clinical Intelligence: Insights to Help Personalize Patient Care
Actionable Clinical Intelligence™: Insights to Help Personalize Patient Care A one-of-a-kind platform that offers new epigenetic and genetic insights to clinicians prescribing the Epi+Gen CHD™ and PrecisionCHD™ tests. These insights are: Generated by integrating the test results with a patient’s uni
Slide 34: Epi+Gen CHD and PrecisionCHD are the Next Generation Tests
Epi+Gen CHD™ and PrecisionCHD™ are the Next Generation Tests for Cardiovascular Medicine Patient 35-75 years old Have not developed signs or symptoms associated with coronary heart disease (CHD) Have not been diagnosed with CHD Have not had a bone marrow transplant Without Epi+Gen CHD™ With Epi+Gen
Slide 35: Epi+Gen CHD and PrecisionCHD are the Next Generation Tests
Epi+Gen CHD™ and PrecisionCHD™ are the Next Generation Tests for Cardiovascular Medicine Patient 35-80 years old Presenting to be evaluated for coronary heart disease (CHD) Have not had a bone marrow transplant Without PrecisionCHD™ With PrecisionCHD™ Requires in-person clinic visit that may take da
Slide 36: CardioInnovate360: A BioPharma Research System
CardioInnovate360™: A BioPharma Research System That Harnessess the Power of Epigenetics, Genetics and Artificial Intelligence CardioInnovate360™ is a research-use-only (RUO) solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management o
Slide 37: HeartRisk: A Cardiovascular Disease Risk Intelligence Platform
HeartRisk™: A Cardiovascular Disease Risk Intelligence Platform to Help Healthcare Stakeholders Make Data-Driven Decisions HeartRisk™ is a a SaaS cardiovascular risk intelligence platform customized to value-based care and other provider organizations, employers, brokers and benefits consultants and
Slide 38: Solutions are Backed by Comprehensive Evidence
Cardio Diagnostics' Solutions are Backed by Comprehensive Evidence that Matters to Healthcare Stakeholders Rigorous clinical and analytical validation of biomarkers and Artificial Intelligence models Dogan et al, 2021, External Validation of Integrated Genetic-Epigenetic Biomarkers for Predicting In
Slide 39: Supply Chain & Laboratory Strategy
Supply Chain & Laboratory Strategy SAMPLE COLLECTION KIT LABORATORY STRATEGY CONTENTS & ASSEMBLY Common kit contents that can be sourced from Favorable agreement in place with an experienced multiple distributors laboratory Identified multiple distributors to diversify supply Refine plan to meet sam
Slide 40: Gross Margin Expansion Opportunity
Gross Margin Expansion Opportunity 1 Currently setting up internal lab 2 Process larger sample batches 3 Increase processing automation 4 Bulk shipping of sample collection kits and/or samples © Cardio Diagnostics Holdings Inc., 2025. All rights reserved.
Slide 41: Product and Company Recognitions
Product and Company Recognitions Disruptive Technology Award 2023 Semifinalist © Cardio Diagnostics Holdings Inc., 2025. All rights reserved.
Cardio Diagnostics Holdings — Investor Presentation (February 2025) on 6ix